Occupational lyssavirus risks and post-vaccination monitoring

Developments in Biologicals

Volumn 125, Issue , 2006, Pages 165-173

  Brookes, S M ^a   Fooks, A R ^a  

^a VETERINARY LABORATORIES AGENCY   (United Kingdom)

Author keywords

Lyssaviruses; Occupational risk; Rabies virus; Vaccine

Indexed keywords

RABIES VACCINE;

ADULT; ANIMAL; BAT; CONFERENCE PAPER; FEMALE; HUMAN; IMMUNIZATION; IMMUNOLOGY; LABORATORY PERSONNEL; MALE; MIDDLE AGED; MONITORING; OCCUPATIONAL EXPOSURE; PARAMEDICAL PERSONNEL; RABIES VIRUS; RISK FACTOR; VACCINATION; VIROLOGY; VIRUS INFECTION;

ADULT; ANIMAL TECHNICIANS; ANIMALS; CHIROPTERA; FEMALE; HUMANS; IMMUNIZATION, SECONDARY; LABORATORY PERSONNEL; LYSSAVIRUS; MALE; MIDDLE AGED; MONITORING, PHYSIOLOGIC; OCCUPATIONAL EXPOSURE; RABIES VACCINES; RHABDOVIRIDAE INFECTIONS; RISK FACTORS; VACCINATION;

EID: 33745548630     PISSN: 14246074     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Conference Paper

References (28)

1. Fooks AR, Brookes SM, Johnson N, McElhinney LM, Hutson AM: European bat lyssaviruses: an emerging zoonosis. Epidemiol Infect 2003; 131 (3): 1029-1039.
2. Anonymous: Department of Health, UK 'Immunisation Against Infectious Disease 1996 - "The Green Book" 1996. Chapter 27 http://www.dh.gov.uk/ assetRoot/04/11/09/70/04110970.pdf.
3. World Health Organization: WHO recommendations on rabies post-exposure treatment and the correct technique of intradermal immunization against rabies. WHO/EMC/ZOO.96.6, 1997. Available at: http://www. who.int/emcdocuments/rabies/ docs/whoemczoo966.pdf
4. World Health Organization: Current WHO guide for rabies pre and post-exposure treatment in humans, 2000. Available at: www.who.int/emc/diseases/ zoo/RabiesPET.pdf
5. World Health Organization. Rabies Bulletin Europe: http://www.who-rabies- bulletin.org/netscapestart.html
6. Bat Conservation Trust, London. Unpublished data, 2004.
7. Morris J, Crowcroft NS, Fooks AR, Brookes SM, Andrews N: Rabies antibody levels in bat handlers in the United Kingdom: A cross-sectional serological survey. Vaccine, in press.
8. Badrane H, Bahloul C, Perrin P, Tordo N: Evidence of two Lyssavirus phylogroups with distinct pathogenicity and immunogenicity. J Virol 2001; 75 (7): 3268-3276.
9. Brookes SM, Parsons G, Johnson N, McElhinney LM, Fooks AR: Rabies human diploid cell vaccine elicits cross-neutralising and cross-protecting immune responses against European and Australian bat lyssaviruses. Vaccine 2005; 23 (32): 4101-4109.
10. Cliquet F, Aubert M, Sagne L: Development of a fluorescent antibody virus neutralisation test (FAVN test) for the quantitation of rabies-neutralising antibody. J Immunol Methods 1998; 212 (1): 79-87.
11. th edition, 2000.
12. Rodrigues FM, Mandke VB, Roumiantzeff M, Rao CV, Mehta JM, Pavri KM, Poonawalla C: Persistence of rabies antibody 5 years after pre-exposure prophylaxis with human diploid cell antirabies vaccine and antibody response to a single booster dose. Epidemiol Infect 1987; 99 (1): 91-95.
13. Briggs DJ, Schwenke JR: Longevity of rabies antibody titre in recipients of human diploid cell rabies vaccine. Vaccine 1992; 10 (2): 125-129.
14. Strady A, Lang J, Lienard M, Blondeau C, Jaussaud R, Plotkin SA: Antibody persistence following preexposure regimens of cell-culture rabies vaccines: 10-year follow-up and proposal for a new booster policy. J Infect Dis 1998; 177 (5): 1290-1295.
15. Aubert M: Can vaccination validated by the titration of rabies antibodies in serum of cats and dogs be an alternative to quarantine measures? Abstr Hyg Comm Dis 1993; 68: R1-R22.
16. Strady C, Jaussaud R, Beguinot I, Lienard M, Strady A: Predictive factors for the neutralizing antibody response following pre-exposure rabies immunization: validation of a new booster dose strategy. Vaccine. 2000; 18 (24): 2661-2667.
17. Strady C, Hung Nguyen V, Jaussaud R, Lang J, Lienard M, Strady A: Pre-exposure rabies vaccination: strategies and cost-minimization study. Vaccine 2001; 19 (11-12): 1416-1424.
18. Nicholson KG, Turner GS, Aoki FY: Immunization with a human diploid cell strain of rabies virus vaccine: two-year results. J Infect Dis 1978; 137 (6): 783-788.
19. Plotkin SA: Rabies vaccine prepared in human cell cultures: progress and perspectives. Rev Infect Dis. 1980; 2 (3): 433-448.
20. Kuwert EK, Barsenbach C, Werner I, Marcus N, Scheiermann N, Grosse-Wilde H, Krumbacher K: Early/High and Low/Late Responders among HDCS Vaccinees, in Kuwert EK, Wiktor TJ, Koprowski H (eds): Cell Culture Rabies Vaccines and their Protective effect in Man. Proceedings of WHO Consultations, Essen 1980. International Green Cross, 1981, pp 100-107.
21. Brown M: Bat Casualty Analysis 2003; Bat Care News 2004; 34: 12-18
22. Bat Care News and 2004; 36: 10-19.
23. Hossain J, Crowcroft NS, Lea G, Brown D, Mortimer PP: Audit of rabies post-exposure prophylaxis in England and Wales in 1990 and 2000. Commun Dis Public Health 2004; 7 (2): 105-111.
24. Bijok U, Barth R, Gruschkau H, Vodopija I, Smerdel S, Kukla H, Geursen R: Clinical trials in healthy volunteers with the new purified chick embryo cell rabies vaccine for man. J Commun Dis 1984; 16 (1): 61-69.
25. Dreesen DW, Fishbein DB, Kemp DT, Brown J: Two-year comparative trial on the immunogenicity and adverse effects of purified chick embryo cell rabies vaccine for pre-exposure immunization. Vaccine 1989; 7 (5): 397-400.
26. Scheiermann N, Baer J, Hilfenhaus J, Marcus I, Zoulek G: Reactogenicity and immunogenicity of the newly developed purified chick embryo cell (PCEC)-rabies vaccine in man. Zentralbl Bakteriol Mikrobiol Hyg [A] 1987; 265 (3-4): 439-450.
27. Sehgal S, Bhattacharya D, Bhardwaj M: Ten year longitudinal study of efficacy and safety of purified chick embryo cell vaccine for pre- and post-exposure prophylaxis of rabies in Indian population. J Commun Dis 1995; 27 (1): 36-43.
28. Messenger SL, Smith JS, Rupprecht CE: Emerging epidemiology of bat-associated cryptic cases of rabies in humans in the United States. Clin Infect Dis 2002; 35 (6): 738-747.